- Home
- PHAR vs CANG Comparison
PHAR vs CANG Comparison
Compare PHAR & CANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CANG
- Stock Information
- Founded
- PHAR 1988
- CANG 2010
- Country
- PHAR Netherlands
- CANG Hong Kong
- Employees
- PHAR N/A
- CANG N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CANG Computer Software: Prepackaged Software
- Sector
- PHAR Health Care
- CANG Technology
- Exchange
- PHAR Nasdaq
- CANG Nasdaq
- Market Cap
- PHAR 951.7M
- CANG 811.9M
- IPO Year
- PHAR N/A
- CANG 2018
- Fundamental
- Price
- PHAR $17.07
- CANG $1.39
- Analyst Decision
- PHAR Strong Buy
- CANG Strong Buy
- Analyst Count
- PHAR 3
- CANG 1
- Target Price
- PHAR $30.00
- CANG $8.00
- AVG Volume (30 Days)
- PHAR 19.8K
- CANG 633.3K
- Earning Date
- PHAR 11-06-2025
- CANG 12-01-2025
- Dividend Yield
- PHAR N/A
- CANG N/A
- EPS Growth
- PHAR N/A
- CANG N/A
- EPS
- PHAR 0.00
- CANG N/A
- Revenue
- PHAR $362,274,000.00
- CANG $396,289,992.00
- Revenue This Year
- PHAR $17.70
- CANG $4,386.58
- Revenue Next Year
- PHAR $12.25
- CANG $18.40
- P/E Ratio
- PHAR $3,068.84
- CANG N/A
- Revenue Growth
- PHAR 26.78
- CANG 495.15
- 52 Week Low
- PHAR $7.35
- CANG $1.16
- 52 Week High
- PHAR $17.76
- CANG $9.66
- Technical
- Relative Strength Index (RSI)
- PHAR 60.37
- CANG 18.39
- Support Level
- PHAR $15.81
- CANG $1.16
- Resistance Level
- PHAR $17.50
- CANG $3.73
- Average True Range (ATR)
- PHAR 0.91
- CANG 0.22
- MACD
- PHAR 0.09
- CANG -0.16
- Stochastic Oscillator
- PHAR 80.47
- CANG 9.34
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in the bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and associated businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives the majority of its revenue from the bitcoin mining business.